Challenges and Triumphs: A Case Series of Drug-resistant Tuberculosis Management in Patients with Coagulation Disorders
Raghul Raj S
Keywords :
Case report, Coagulation disorders, Combined factors V and VIII deficiency, Hemophilia, Multidrug resistant tuberculosis
Citation Information :
S RR. Challenges and Triumphs: A Case Series of Drug-resistant Tuberculosis Management in Patients with Coagulation Disorders. Indian J Respir Care 2024; 13 (4):265-267.
Managing drug-resistant tuberculosis (MDR-TB) in patients with underlying coagulation disorders such as hemophilia and combined factor V and VIII deficiency presents significant challenges due to the risk of bleeding and potential drug-related complications. This case series details two unique instances of MDR-TB in such patients, exploring the complexities of treatment. Tuberculosis, known to induce a hypercoagulable state, can further complicate existing coagulation abnormalities. Using individualized shorter all-oral MDR-TB regimens alongside careful monitoring, both patients were successfully treated without severe bleeding episodes or deterioration in their coagulation profiles. This series highlights the importance of therapeutic approaches with close interdisciplinary collaboration to manage such cases effectively and improve patient outcomes.
Kaur G, Mundhe V, PUS, et al. Pulmonary tuberculosis induced coagulation disorder: a case series. Int J Med Sci Curr Res Rev 2023;6(1):81–90. DOI: 10.5281/zenodo.7554959
Central TB Division Ministry of Health and Family Welfare, http://www.tbcindia.gov.in March 2023.
Suryakusumah L, Tabri NA, Saleh S, et al. Hemostatic parameters in pulmonary tuberculosis patients after intensive phase treatment. Caspian J Intern Med 2021;12(3):294–298. DOI: 10.22088/cjim.12.3.294
Toro AU, Ortega JG. Acquired hemophilia and tuberculosis: case report and literature review. Hematol Transfus Int J 2017;5(5):315–317. DOI: 10.15406/htij.2017.05.00135
Conradie F, Bagdasaryan TR, Borisov S, et al. Bedaquiline-pretomanid-linezolid regimens for drug-resistant tuberculosis. N Engl J Med 2022;387(9):810–823. DOI: 10.1056/NEJMoa2119430
Report of the Guideline Development Group Meeting on the use of bedaquiline in the treatment of multidrug-resistant tuberculosis. A review of available evidence. (2016). Geneva: World Health Organization; 2017. Licence: CC BY-NC-SA 3.0 IGO.
Takahashi Y, Takesue Y, Nakajima K, et al. Risk factors associated with the development of thrombocytopenia in patients who received linezolid therapy. J Infect Chemother 2011;17(3):382–327. DOI: 10.1007/s10156-010-0182-1
Padmapriyadarsini C, Oswal VS, Jain CD, et al. Effectiveness and safety of varying doses of linezolid with bedaquiline and pretomanid in treatment of drug-resistant pulmonary tuberculosis: open-label, randomized clinical trial. Clin Infect Dis 2024:ciae388. DOI: 10.1093/cid/ciae388
